Add to Watchlist
View Current for ARQT
View SuperFeed for ARQT
View Charts for ARQT
Add or remove $ARQT from your watchlists:
Hang tight! We're updating your watchlist data.
This might take a minute...
You have not created a stock watchlist. Create one now to track $ARQT!
Arcutis Biotherapeutics Inc
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lea… more
Explore popular threads around $ARQT
There are no threads for this stock
Go to Thread Explorer
Explore recent charts, graphs, and media
There are no charts for this stock
Get the latest breaking news from the community
There is no recent news for this stock
Loading news, hang tight...
Google Search Trends - Past 12 months
Instantly visualize search trends for this specific symbol
Company ProfileArcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical formulation of ivarmacitinib designed to reach deeper into the skin in order to treat alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Market Cap Type: Small